title: The multiple myeloma bone eco-system and its relation to oncogenesis.
abstract: Pure lytic bone lesions are the hallmark of myeloma (MM). MM is the only hematological malignancy associated with lytic bone lesions and the mechanisms of bone destruction are well documented both at the cellular and molecular levels. An uncoupling bone process characterizes MM, with stimulation of bone resorption and inhibition of bone formation. The capacity of MM cells to directly or indirectly inhibit bone formation is specific of MM, although many carcinomas have the capacity to stimulate bone resorption, directly or indirectly in a similar way to MM. Few MM do not develop bone lesions, while true sclerotic MM remain exceptional. Inhibition of bone formation is the major event explaining the transition from MGUS to overt MM. It is now well documented that bone cells regulate MM cell growth, osteoclast stimulating MM cell growth and osteoblasts inhibiting it. Progression of MM from MGUS is characterized by the selection of MM clones able to inhibit osteoblasts, favoring tumor growth. These data underline the interest of new treatments able to regenerate bone.
authors.affiliation: Institut de cancérologie de l'Ouest, université d'Angers, 2, rue Moll, 49933 Angers cedex 9, France; CRCNA UMR Inserm 892, IRS UN, 44000 Nantes, France. Electronic address: francois-regis.bataille@ico.unicancer.fr.
authors.forename: R
authors.initials: R
authors.lastname: Bataille
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001862:Bone Resorption / Q000209:etiology; D001842:Bone and Bones / Q000473:pathology*; D000069286:Bortezomib / Q000494:pharmacology / Q000627:therapeutic use; D002450:Cell Communication; D002454:Cell Differentiation; D002471:Cell Transformation, Neoplastic; D002999:Clone Cells / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D058990:Molecular Targeted Therapy; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000473:pathology; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D009363:Neoplasm Proteins / Q000502:physiology; D014411:Neoplastic Stem Cells / Q000473:pathology; D010006:Osteoblasts / Q000473:pathology / Q000502:physiology; D010010:Osteoclasts / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D010012:Osteogenesis; D010014:Osteolysis / Q000209:etiology / Q000473:pathology*; D012641:Selection, Genetic; D017154:Stromal Cells / Q000502:physiology; D059016:Tumor Microenvironment
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D000069286:Bortezomib
keywords: Bone disease; Bone formation; Bone resorption; Formation osseuse; Maladie osseuse; Multiple myeloma; Myélome multiple; Résorption osseuse